Promising treatment brings new hope for patients with chronic Lyme disease
Published Friday, November 20, 2020
- foibles of testing
- polarization within the medical community and with public ‘authorities’
- hotly contested issue of chronic Lyme/MSIDS
- fear experienced by doctors who treat chronic Lyme: https://madisonarealymesupportgroup.com/2018/12/15/everything-about-lyme-disease-is-steeped-in-controversy-now-some-doctors-are-too-afraid-to-treat-patients/
- severity of the disease(s)
- tick proliferation – which despite the continual propaganda has been shown to be caused by migrating birds/animals not climate change: https://madisonarealymesupportgroup.com/2018/11/07/ticks-on-the-move-due-to-migrating-birds-and-photoperiod-not-climate-change/
- https://madisonarealymesupportgroup.com/2017/03/24/one-pill-of-doxy-only-reduces-prevalence-of-rash-not-lyme-disease/ Excerpt:
Daniel J. Cameron, MD MPH, states there has only been one study (Nadelman et al) on the effectiveness of 1 pill of doxycycline and only found a reduction in the number of erythema migraines (EM) rashes compared to the placebo group. According to him, the IDSA 1 pill of doxy approach started in 2006 despite the fact that three previous prophylactic antibiotic trials for a tick bite had failed.
Only one study in 2001 tested this hypothesis at one hospital in New York.
For the study, the bullseye rash was the diagnostic criteria to determine if doxy prevented LD. The study actually showed that people bitten by nymphs were more likely to develop a bullseye rash and therefore diagnosed with LD in comparison with those bitten by an adult tick. None of those bitten by adult ticks developed a bullseye rash.
The Bullseye is a poor indicator of LD.
Only 50% with LD got any kind of rash and only 9% developed a bullseye.
Two pills used at the time of tick bite by a nymph prevented people from getting the bullseye – so they were not diagnosed as having LDand were excluded from the study.
So, will 2 pills of doxy prevent Lyme?
So much for evidence based medicine.
“OK, now this is exciting,” he said. “Disulfram (DSF) is a breakthrough because it is one of only two or three medications that are known to specifically target the slow-growth phase of Lyme that regular antibiotics do not eradicate.”“What has surprised me is how patients improve with very little of it. Prior to DSF, the conventional combinations of antibiotics would make most patients feel quite a bit better, but they would often say that their ‘brain fog’ and fatigue never quite went away. These two symptoms are often completely and rapidly resolved with DSF,” Dr. Cook said.
Dr. Cook states that while DSM isn’t for everyone, those with long-standing symptoms and those who have failed to improve on antibiotics are good candidates.
For more on DSM:
A word of caution, however – DSM can cause toxicity which can cause psychosis, among other symptoms – something I experienced first-hand: